Browsing by Author "Mercan, Ridvan"

Now showing 1 - 3 of 3

Diagnostic dilemma of paraneoplastic arthritis: Case series
(Wiley-blackwell, 2014-07-01) Kısacık, Bünyamin; Onat, Ahmet M.; Kaşifoğlu, Timuçin; Pehlivan, Yavuz; Pamuk, Ömer N.; Dönmez, Salim; Bilge, Sule Y.; Yilmaz, Sedat; Erdem, Hakan; Mercan, Ridvan; Özturk, Mehmet A.; Beş, Cemal; Soy, Mehmet; Erten, Sukran; Çobankara, Veli; Senel, Soner; Öner, Fatma A.; Direskeneli, Haner; Yılmaz, Sema; Yazıcı, Ayten; Emmungil, Hakan; Aksu, Kenan; Kul, Seval; Çetin, Gozde Y.; Sayarlıoğlu, Mehmet; DALKILIÇ, HÜSEYİN EDİZ; 0000-0002-6265-5227; 0000-0003-1537-2192; 0000-0003-1096-7306; 0000-0003-1710-7018; 0000-0003-0717-8365; 0000-0003-2598-5806; 0000-0002-4839-3777; 0000-0003-2167-4509; 0000-0001-5184-4404; JUV-4187-2023; JFJ-3399-2023; W-3342-2017; AAT-3636-2020; AAG-7687-2020; IZE-6133-2023; AAG-8227-2021; AAR-2072-2020; AAD-1796-2021; HLH-8218-2023; J-9960-2019; AAS-5508-2020; AAD-5233-2020
Objectives: Paraneoplastic arthritis (PA) may mimic rheumatic diseases. While presenting the demographic and laboratory features of the patients diagnosed with PA, this study also aims to provide possible appropriate tools to differentiate the PA cases from early rheumatoid arthritis (ERA).Methods: Sixty-five patients with PA (male/female: 43/22) from 15 different rheumatology clinics and 50 consecutive patients with ERA (male/female: 13/37) fulfilling the 2010 American College of Rheumatology (ACR) criteria for the diagnosis if the RA from Gaziantep Rheumatology Early Arthritis Trial (GREAT) as controls who were diagnosed at least 12 months before, were enrolled into study.Results: Mean ages of the patients with PA and ERA were 50.2 +/- 15.3, and 42.7 +/- 12.3, respectively, and the mean ages of the patients with PA were significantly higher than the ERA. Unlike the ERA patients, in our case series PA was predominantly observed among males. Oligoarthritis was significantly higher in solid tumors in contrast to ERA (P = 0.001). Polyarthritis and symmetric arthritis were significantly higher in the ERA group in contrast to all malignancies (P = 0.001). Rheumatoid factor (RF) and anticyclic citrullinated peptide antibody (anti-CCP) positivity were significantly higher in the ERA group (each P = 0.001). Lactic dehydrogenase levels of hematologic malignancies were significantly higher than other groups (each, P = 0.001).Conclusions: ERA patients had more symmetric joint involvement than PA; laboratory markers could be also an alternative where there is high RF and anti-CCP positivity with antibody levels among the ERA patients. Finally, the demographic features can be used as differentiating
In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
(Springer Heidelberg, 2021-07-05) Yağız, Burcu; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; Kiraz, Sedat; Yazısız, Veli; Kucuksahin, Orhan; Erden, Abdulsamet; Kanitez, Nilufer Alpay; Kimyon, Gezmis; Emmungil, Hakan; Bilge, Sule Yasar; Kasifoglu, Timucin; Bes, Cemal; Bolek, Ertugrul Cagri; Bilgin, Emre; Karatas, Ahmet; Kelesoglu, Bahar; Ersozlu, Duygu; Gonullu, Emel Orge; Mercan, Ridvan; Yilmaz, Sedat; Karadag, Omer; Akar, Servet; Ertenli, Ihsan; Kalyoncu, Umut; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; 0000-0003-0298-4157 ; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022
We wanted to see how close we could get to our goal of treating rheumatoid arthritis (RA) without the use of glucocorticoids (GCs) in the disease-modifying antirheumatic drugs (DMARDs) era using real-life data. Established in 2017, the TReasure database is a web-based, prospective, observational cohort for Turkey. As of May 2019, there were 2,690 RA patients recorded as receiving biologic and targeted synthetic DMARDs (bDMARDs and tsDMARDs) therapy. At the start of the bDMARDs or tsDMARDs, patients with follow-up visits of at least 3 months were registered. At the time of registration and the last visit, doses of GCs were recorded and it was determined if the target dose of <= 7.5 mg was achieved. During registration and follow-up, 23.4% of the patients did not receive GCs and 76.5% of the patients received GCs at any time. GCs could be stopped after 59 (25-116) months in 28.4% of these patients, but 71.6% of patients were still using GC. The target GC dose could not be achieved in 18.2% of these patients (n = 352). The rate of continuing to use GC was significantly higher in women, in the elderly, those with rheumatoid factor (RF) positive, with higher Visual Analog Scale (VAS) pain and Disease Activity Score (DAS)-28. The initial GC dose of >= 7.5 mg/day was found to be crucial in not reaching the GC target dose (p < 0.001, OR 39.0 (24.1-63.2)). The initial GC dose of >= 7.5 mg/day, female gender, age, RF positivity, high DAS28, and VAS pain level were all highly related for GC continuation. Despite the use of DMARDs, our data revealed that we are still far from achieving our goal of treating RA without using steroids.
Psart-id inception cohort: Clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis
(Oxford University, 2021-04-01) Ayan, Gizem; Aydin, Sibel Zehra; Kimyon, Gezmis; Ozisler, Cem; Tinazzi, Ilaria; Dogru, Atalay; Omma, Ahmet; Kilic, Levent; Kucuksahin, Orhan; Gonullu, Emel; Can, Meryem; Ylldlz, Fatih; Solmaz, Dilek; Bayindir, Ozun; Esmen, Serpil Ergulu; Ersozlu, Emine Duygu; Duruoz, Mehmet Tuncay; Akyol, Lutfi; Kucuk, Adem; Bes, Cemal; Erden, Abdulsamet; Bakirci, Sibel; Kasifoglu, Timucin; Kalyoncu, Umut; Balkarli, Aye; Dalkilic, Ediz; Cetin, Gozde Yildirim; Cinar, Muhammet; Mercan, Ridvan; Yazisiz, Veli; Dalkılıç, Ediz; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-1889-9619; 0000-0001-7475-3927; 0000-0002-6990-4206; 0000-0003-3628-8870; 0000-0002-9035-689X; 0000-0003-3584-2788; 0000-0001-8028-1671; 0000-0002-8084-2018; 0000-0002-2745-7700; 0000-0001-9680-7535; 0000-0002-6150-3539; GQQ-3193-2022; I-2307-2016; W-2397-2019; K-7985-2019; B-1448-2016; AAK-7851-2021; HLP-4890-2023; GZA-3287-2022; P-2555-2018; C-1808-2016
Objectives. Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts.Methods. PsArt-ID (Psoriatic Arthritis- International Database) is a multicentre registry. From that registry, patients with a diagnosis of PsA up to 6 months were classified as the inception cohort (n=388). Two periods were identified for the established cohort: Patients with PsA diagnosis within 5-10 years (n = 328), >= 10 years (n = 326). Demographic, clinical characteristics, treatment strategies, outcomes were determined for the inception cohort and compared with the established cohorts.Results. The mean (S.D.) age of the inception cohort was 44.7 (13.3) and 167/388 (43.0%) of the patients were male. Polyarticular and mono-oligoarticular presentations were comparable in the inception and established cohorts. Axial involvement rate was higher in the cohort of patients with PsA >= 10 years compared with the inception cohort (34.8% vs 27.7%). As well as dactylitis and nail involvement (P = 0.004, P = 0.001 respectively). Both enthesitis, deformity rates were lower in the inception cohort. Overall, 13% of patients in the inception group had a deformity. MTX was the most commonly prescribed treatment for all cohorts with 10.7% of the early PsA patients were given anti-TNF agents after 16 months.Conclusion. The real-life experience in PsA patients showed no significant differences in the disease pattern rates except for the axial involvement. The dactylitis, nail involvement rates had increased significantly after 10 years from the diagnosis and the enthesitis, deformity had an increasing trend over time.